# MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue

> **NCT02680535** · NA · COMPLETED · sponsor: **Nanospectra Biosciences, Inc.** · enrollment: 45 (actual)

## Conditions studied

- Neoplasms of the Prostate

## Interventions

- **DEVICE:** AuroShell particle infusion

## Key facts

- **NCT ID:** NCT02680535
- **Lead sponsor:** Nanospectra Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2020-10
- **Final completion:** 2020-10
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2021-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02680535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02680535, "MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02680535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*